Anacardic acid potentiates apoptosis induced by TNF and chemotherapeutic agents
| Cell lines . | Apoptosis, % . | |||||||
|---|---|---|---|---|---|---|---|---|
| Medium . | TNF . | Cisplatin . | Doxorubicin . | |||||
| Anacardic acid, μmol/L | 0 | 25 | 0 | 25 | 0 | 25 | 0 | 25 |
| KBM-5 | 0 ± 0.6 | 3.5 ± 1.9 | 1.7 ± 1.2 | 32.8 ± 1.0 | 12.3 ± 3.4 | 33.8 ± 5.5 | 9.3 ± 2.8 | 31.8 ± 5.4 |
| Jurkat | 0 ± 0.6 | 4.1 ± 1.1 | 3.1 ± 0.8 | 26.7 ± 2.7 | 6.1 ± 1.0 | 24.6 ± 1.8 | 3.2 ± 0.8 | 29.6 ± 2.7 |
| H1299 | 0 ± 0.5 | 4.4 ± 1.2 | 5.4 ± 0.9 | 35.8 ± 5.7 | 8.9 ± 2.1 | 34.9 ± 4.8 | 5.6 ± 1.4 | 29.7 ± 4.7 |
| Du145 | 0 ± 0.9 | 7.6 ± 2.0 | 2.5 ± 1.1 | 29.3 ± 1.1 | 3.2 ± 0.9 | 31.7 ± 2.6 | 7.2 ± 3.1 | 27.3 ± 0.8 |
| SCC4 | 0 ± 0.8 | 3.8 ± 1.7 | 6.7 ± 4.1 | 30.7 ± 5.4 | 7.5 ± 3.1 | 34.6 ± 4.2 | 6.4 ± 1.2 | 33.6 ±4.1 |
| Cell lines . | Apoptosis, % . | |||||||
|---|---|---|---|---|---|---|---|---|
| Medium . | TNF . | Cisplatin . | Doxorubicin . | |||||
| Anacardic acid, μmol/L | 0 | 25 | 0 | 25 | 0 | 25 | 0 | 25 |
| KBM-5 | 0 ± 0.6 | 3.5 ± 1.9 | 1.7 ± 1.2 | 32.8 ± 1.0 | 12.3 ± 3.4 | 33.8 ± 5.5 | 9.3 ± 2.8 | 31.8 ± 5.4 |
| Jurkat | 0 ± 0.6 | 4.1 ± 1.1 | 3.1 ± 0.8 | 26.7 ± 2.7 | 6.1 ± 1.0 | 24.6 ± 1.8 | 3.2 ± 0.8 | 29.6 ± 2.7 |
| H1299 | 0 ± 0.5 | 4.4 ± 1.2 | 5.4 ± 0.9 | 35.8 ± 5.7 | 8.9 ± 2.1 | 34.9 ± 4.8 | 5.6 ± 1.4 | 29.7 ± 4.7 |
| Du145 | 0 ± 0.9 | 7.6 ± 2.0 | 2.5 ± 1.1 | 29.3 ± 1.1 | 3.2 ± 0.9 | 31.7 ± 2.6 | 7.2 ± 3.1 | 27.3 ± 0.8 |
| SCC4 | 0 ± 0.8 | 3.8 ± 1.7 | 6.7 ± 4.1 | 30.7 ± 5.4 | 7.5 ± 3.1 | 34.6 ± 4.2 | 6.4 ± 1.2 | 33.6 ±4.1 |
Cells (5 × 103/well) were seeded in triplicate in 96-well plates; 12 hours later, cells were pre-exposed to anacardic acid (25 μmol/L) for 4 hours and then to TNF (1 nmol/L), cisplatin (3 μg/mL), or doxorubicin (0.1 μmol/L) for 24 hours. Apoptosis was analyzed by the MTT method.